Open AccessCancer‐testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer
Author(s) -
Okabayashi Koji,
Fujita Tomonobu,
Miyazaki Junichiro,
Okada Tsutomu,
Iwata Takashi,
Hirao Nobumaru,
Noji Shinobu,
Tsukamoto Nobuo,
Goshima Naoki,
Hasegawa Hirotoshi,
Takeuchi Hiroya,
Ueda Masakazu,
Kitagawa Yuko,
Kawakami Yutaka
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2012.02355.x
Subject(s) - cancer , hazard ratio , immunohistochemistry , antigen , biology , biomarker , metastasis , immunotherapy , cancer research , oncofetal antigen , survival analysis , oncology , medicine , immunology , confidence interval , biochemistry , tumor associated antigen
Esophageal squamous cell cancer ( ESCC ) is one of the most common lethal tumors in the world, and development of new diagnostic and therapeutic methods is needed. In this study, cancer‐testis antigen, BORIS , was isolated by functional cDNA expression cloning using screening technique with serum IgG Abs from ESCC patients. BORIS was previously reported to show cancer‐testis antigen like expression, but its immunogenicity has remained unclear in cancer patients. BORIS was considered to be an immunogenic antigen capable of inducing IgG Abs in patients with various cancers, including four of 11 ESCC patients. Immunohistochemical study showed that the BORIS protein was expressed in 28 of 50 (56%) ESCC tissues. The BORIS expression was significantly associated with lymph node metastasis in ESCC patients with pT 1 disease ( P = 0.036). Furthermore, the patients with BORIS ‐positive tumors had a poor overall survival (5‐year survival rate: BORIS ‐negative 70.0% vs BORIS ‐positive 29.9%, log‐rank P = 0.028) in K aplan– M eier survival analysis and log‐rank test. Multivariate C ox proportional hazard model demonstrated that BORIS expression was an independent poor prognostic factor (hazard ratio = 4.158 [95% confidence interval 1.494–11.57], P = 0.006). Downregulation of BORIS with specific si RNA s resulted in decreased cell proliferation and invasion ability of ESCC cell lines. BORIS may be a useful biomarker for prognostic diagnosis of ESCC patients and a potential target for treatment including by BORIS ‐specific immunotherapy and molecular target therapy.